Text Size

Efficacy and Safety Study of an Oral Contraceptive in Healthy Females

This study has been completed.
Sponsor:
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00206583
First received: September 12, 2005
Last updated: August 5, 2011
Last verified: August 2011
History of Changes
  Purpose

The purpose of this study is to determine whether the study drug is safe and effective in the prevention of pregnancies in a large group of volunteers.


Condition Intervention Phase
Contraception
 Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Multicenter, Open-label Uncontrolled Study to Investigate the Efficacy and Safety of a 4-phasic Oral Contraceptive SH T0065 in a 28-day Regimen for 13 Cycles in Healthy Female Subjects

Resource links provided by NLM:

MedlinePlus related topics: Birth Control
U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Number of unintended pregnancies after 1 year [ Time Frame: Throughout 1 year of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Bleeding pattern and cycle control parameters after 1 year [ Time Frame: Throughout 1 year of treatment ] [ Designated as safety issue: No ]

Enrollment: 498
Study Start Date: March 2005
Study Completion Date: July 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
n/a
 Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)

Detailed Description:

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy women between the ages of 18 and 35 years requiring contraception

Exclusion Criteria:

  • Pregnancy, lactation, and contraindication of combined oral contraceptive
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00206583

  Show 29 Study Locations
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Click here and search for drug information provided by the FDA.  This link exits the ClinicalTrials.gov site
Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Therapeutic Area Head, Bayer HealthCare Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT00206583     History of Changes
Other Study ID Numbers: 90959, 304742
Study First Received: September 12, 2005
Last Updated: August 5, 2011
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Additional relevant MeSH terms:
Contraceptive Agents
Contraceptives, Oral
Reproductive Control Agents
Physiological Effects of Drugs
 Pharmacologic Actions
Therapeutic Uses
Contraceptive Agents, Female

ClinicalTrials.gov processed this record on May 19, 2013